The Pharmacogenomics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 140 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of pharmacogenomics dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in pharmacogenomics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading pharmacogenomics deals since 2009. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top big pharma companies with a brief summary followed by a comprehensive listing of pharmacogenomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since January 2009. The chapter is organized by specific pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in pharmacogenomics partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pharmacogenomics technologies and products.
Pharmacogenomics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pharmacogenomics trends and structure of deals entered into by leading companies worldwide.
Pharmacogenomics Partnering Terms and Agreements includes:
- Trends in pharmacogenomics dealmaking in the biopharma industry since 2009
- Analysis of pharmacogenomics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life pharmacogenomics deals
- Access to over 140 pharmacogenomics deal records and contract documents where available
- The leading pharmacogenomics deals by value since 2009
- Most active pharmacogenomics dealmakers since 2009
- The leading pharmacogenomics partnering resources
In Pharmacogenomics Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Pharmacogenomics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 140 pharmacogenomics deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise pharmacogenomisc rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Pharmacogenomics Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of pharmacogenomics deal trends since 2009
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of pharmacogenomics agreements with numerous real life case studies
- Access to over 140 pharmacogenomics online deals entered into by the world’s biopharma companies
- Detailed access to actual pharmacogenomics contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a pharmacogenomics agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in pharmacogenomics dealmaking
2.2. Pharmacogenomics partnering over the years
2.3. Big pharma pharmacogenomics dealmaking activity
2.4. Most active Pharmacogenomics dealmakers
2.5. Pharmacogenomics partnering by deal type
2.6. Pharmacogenomics partnering by disease type
2.7 Average deal terms for Pharmacogenomics
2.7.1 Pharmacogenomics headline values
2.7.2 Pharmacogenomics upfront payments
2.7.3 Pharmacogenomics milestone payments
2.7.4 Pharmacogenomics royalty rates
Chapter 3 – Big pharma pharmacogenomics deals
3.2. How to use big pharma pharmacogenomics partnering deals
3.3. Big pharma pharmacogenomics partnering company profiles
Johnson & Johnson
Merck & Co
Chapter 4 – Pharmacogenomics dealmaking directory
4.2. Company A-Z
ALS Emergency Treatment Fund
American Society of Clinical Oncology (ASCO)
Beijing Health Bureau
Caliper Life Sciences
Caris Life Sciences
Case Western Reserve University
Catholic Health Initiatives
Companion Dx Reference Lab
CompanionDx Reference Lab
Dana-Farber Cancer Institute
Essential Molecular Testing
Food and Drug Administration (FDA)
Fox Chase Cancer Center
German Cancer Research Center
Government of Germany
Helmholtz Institute in Saarbrucken
Hospices Civils de Lyon
Hospital for Special Surgery
Inova Health System
Johns Hopkins University
Johnson & Johnson
Laboratory Corporation of America
Massachusetts General Hospital
MD Anderson Cancer Center
Medco Health Solutions
Medco Research Institute
Medical University South Carolina
Memorial Sloan Kettering Cancer Center
Merck and Co
Montreal Heart Institute
National Research Council Canada
National Science Foundation
New York University
Population Genetics Technologies
Predictive Biomarker Sciences
PROOF Centre of Excellence for Commercialization and Research
QIAGEN (Suzhou) Translational Medicine Center
Research Institute of the Hospital Universitari Vall d'Hebron
Russian Nanotechnology Corporation
Rx Review Service
Sanford Burnham Institute
Scripps Translational Science Institute
Shanghai Centers for Disease Control and Prevention
Shanghai Institutes of Preventative Medicine
Smart Personalized Medicine
Stone Ridge Technology
TGen Drug Development
The Biomarker Factory
UAB Research Foundation
United Kingdom Critical Care Genomics
University of Bergen
University of California San Francisco
University of Montreal Pharmacogenomics Centre
University of Pittsburgh
University of Wurzburg
4.3. By deal type
4.4. By therapy area
Central nervous system
Chapter 5 –Pharmacogenomics dealmaking by technology type
5.2. Deals by pharmacogenomics type
Chapter 6 – Pharmacogenomics partnering resource center
6.1. Online pharmacogenomics partnering
6.2. Pharmacogenomics partnering events
6.3. Further reading on pharmacogenomics dealmaking
Appendix 1 – Deal type definitions
Appendix 2 – Example pharmacogenomics partnering agreement
About Wildwood Ventures
Order Form – Upgrades to subscription access products
Recent titles from Current Partnering
Order Form – Reports
List of Chart
Figure 1: Pharmacogenomics partnering since 2009
Figure 2: Big pharma – top 50 – pharmacogenomics deals 2009 to 2014
Figure 3: Big pharma Pharmacogenomics deal frequency – 2009 to 2014
Figure 4: Active pharmacogenomics dealmaking activity– 2009 to 2014
Figure 5: Pharmacogenomics partnering by deal type since 2009
Figure 6: Pharmacogenomics partnering by disease type since 2009
Figure 7: Pharmacogenomics deals with a headline value by year- 2014
Figure 8: Pharmacogenomics deals with a headline value by year- 2013
Figure 9: Pharmacogenomics deals with a headline value by year- 2012
Figure 10: Pharmacogenomics deals with a headline value by year- 2011
Figure 11: Pharmacogenomics deals with a headline value by year- 2010
Figure 12: Pharmacogenomics deals with a headline value by year- 2009
Figure 13: Pharmacogenomics deals with an upfront value by year- 2014
Figure 14: Pharmacogenomics deals with an upfront value by year- 2013
Figure 15: Pharmacogenomics deals with an upfront value by year- 2012
Figure 16: Pharmacogenomics deals with an upfront value by year- 2011
Figure 17: Pharmacogenomics deals with an upfront value by year- 2010
Figure 18: Pharmacogenomics deals with an upfront value by year- 2009
Figure 19: Pharmacogenomics deals with a milestone value by year- 2014
Figure 20: Pharmacogenomics deals with a milestone value by year- 2013
Figure 21: Pharmacogenomics deals with a milestone value by year- 2012
Figure 22: Pharmacogenomics deals with a milestone value by year- 2011
Figure 23: Pharmacogenomics deals with a milestone value by year- 2010
Figure 24: Pharmacogenomics deals with a milestone value by year- 2009
Figure 25: Pharmacogenomics deals with a royalty rate by year- 2014
Figure 26: Pharmacogenomics deals with a royalty ratvalue by year- 2013
Figure 27: Pharmacogenomics deals with a royalty rate by year- 2012
Figure 28: Pharmacogenomics deals with a royalty rate by year- 2011
Figure 29: Pharmacogenomics deals with a royalty rate by year- 2010
Figure 30: Pharmacogenomics deals with a royalty rate value by year- 2009
Figure 31: Online partnering resources
Figure 32: Forthcoming partnering events
Figure 33: Deal type definitions
Figure 34: Pharmacogenomics partnering agreement between GlaxoSmithKline and Response Genetics, May 2010